271 related articles for article (PubMed ID: 23523308)
1. MYC-y mice: from tumour initiation to therapeutic targeting of endogenous MYC.
Morton JP; Sansom OJ
Mol Oncol; 2013 Apr; 7(2):248-58. PubMed ID: 23523308
[TBL] [Abstract][Full Text] [Related]
2. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract][Full Text] [Related]
3. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
4. Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia.
Mahauad-Fernandez WD; Rakhra K; Felsher DW
Methods Mol Biol; 2021; 2318():297-312. PubMed ID: 34019298
[TBL] [Abstract][Full Text] [Related]
5. MYC in oncogenesis and as a target for cancer therapies.
Albihn A; Johnsen JI; Henriksson MA
Adv Cancer Res; 2010; 107():163-224. PubMed ID: 20399964
[TBL] [Abstract][Full Text] [Related]
6. Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.
Xin B; Yamamoto M; Fujii K; Ooshio T; Chen X; Okada Y; Watanabe K; Miyokawa N; Furukawa H; Nishikawa Y
Oncogene; 2017 Sep; 36(36):5087-5097. PubMed ID: 28481866
[TBL] [Abstract][Full Text] [Related]
7.
Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
[TBL] [Abstract][Full Text] [Related]
8. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.
Hoellein A; Fallahi M; Schoeffmann S; Steidle S; Schaub FX; Rudelius M; Laitinen I; Nilsson L; Goga A; Peschel C; Nilsson JA; Cleveland JL; Keller U
Blood; 2014 Sep; 124(13):2081-90. PubMed ID: 25143484
[TBL] [Abstract][Full Text] [Related]
9. Concepts to Target MYC in Pancreatic Cancer.
Wirth M; Mahboobi S; Krämer OH; Schneider G
Mol Cancer Ther; 2016 Aug; 15(8):1792-8. PubMed ID: 27406986
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases.
Sipos F; Firneisz G; Műzes G
World J Gastroenterol; 2016 Sep; 22(35):7938-50. PubMed ID: 27672289
[TBL] [Abstract][Full Text] [Related]
11. Minimal cooperation between mutant Hras and c-myc or TGFα in the regulation of mouse hepatocyte growth or transformation in vivo.
Stein TJ; Bowden M; Sandgren EP
Liver Int; 2011 Oct; 31(9):1298-305. PubMed ID: 22093452
[TBL] [Abstract][Full Text] [Related]
12. Taking on challenging targets: making MYC druggable.
Horiuchi D; Anderton B; Goga A
Am Soc Clin Oncol Educ Book; 2014; ():e497-502. PubMed ID: 24857145
[TBL] [Abstract][Full Text] [Related]
13. A big step for MYC-targeted therapies.
Atibalentja DF; Deutzmann A; Felsher DW
Trends Cancer; 2024 May; 10(5):383-385. PubMed ID: 38580534
[TBL] [Abstract][Full Text] [Related]
14. The long journey to bring a Myc inhibitor to the clinic.
Whitfield JR; Soucek L
J Cell Biol; 2021 Aug; 220(8):. PubMed ID: 34160558
[TBL] [Abstract][Full Text] [Related]
15. Distinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression.
Wang H; Wang P; Xu M; Song X; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
Cell Death Dis; 2021 Feb; 12(2):200. PubMed ID: 33608500
[TBL] [Abstract][Full Text] [Related]
16. c-Myc and eIF4F constitute a feedforward loop that regulates cell growth: implications for anticancer therapy.
Lin CJ; Malina A; Pelletier J
Cancer Res; 2009 Oct; 69(19):7491-4. PubMed ID: 19773439
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis.
Sluss HK; Gannon H; Coles AH; Shen Q; Eischen CM; Jones SN
Mol Cancer Res; 2010 Feb; 8(2):216-22. PubMed ID: 20145032
[TBL] [Abstract][Full Text] [Related]
18. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics.
Chen BJ; Wu YL; Tanaka Y; Zhang W
Int J Biol Sci; 2014; 10(10):1084-96. PubMed ID: 25332683
[TBL] [Abstract][Full Text] [Related]
19. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
20. The many faces of c-MYC.
Pelengaris S; Khan M
Arch Biochem Biophys; 2003 Aug; 416(2):129-36. PubMed ID: 12893289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
